Meanwhile, access to Wegovy has improved slightly compared to last year, due in part to CVS Caremark’s decision to prefer Wegovy on its standard formulary.

Serena Williams recently shared that she started taking the GLP-1 drug Zepbound after having her two children. The tennis ...

Zepbound led to an average weight loss of 20.2 percent compared to Wegovy's 13.7 percent. We talked with healthcare experts to understand the study's findings, what sets these drugs apart and how ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical ...

When the trial concluded, individuals who took Zepbound lost roughly 20% of their body weight on average, compared with almost 14% loss for those who took Wegovy.

Novo Nordisk said on Monday it is offering its diabetes drug Ozempic for $499 per month to eligible cash-paying type 2 ...

Millions of Americans who have dropped pounds and boosted their health using popular obesity drugs like Wegovy are facing a ...

In a study of more than 1,600 adults with type 2 diabetes, those who received the highest dose of orforglipron on average shed 10.5% of their weight.

The once-daily pill also helped 75 per cent of patients who received the highest dose of orforglipron lower their A1C level - ...

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22.8 kilograms) over 72 weeks, while those who took semaglutide, or Wegovy, lost about 33 ...

Zepbound generated $4.9 billion in global sales last year. Wegovy brought in nearly $8.8 billion (58.2 billion Danish kroner). Access and affordability have limited wider use of the drugs.

Zepbound generated $4.9 billion in global sales last year. Wegovy brought in nearly $8.8 billion (58.2 billlion Danish kroner). Access and affordability have limited wider use of the drugs.